BridgeBio Pharma announced the initiation of a scientific collaboration with the CarDS Lab, led by cardiologist-data scientist, Rohan Khera, M.D., M.S. at Yale School of Medicine, to help address the underdiagnosis of ATTR-CM. The TRACE-AI Network Study will be deployed as a novel paradigm of large-scale federated screening for ATTR-CM that harnesses a central repository of validated AI tools across multiple participating sites to evaluate the scale of ATTR-CM underdiagnosis across the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
- BridgeBio launches MyAchonJourney online resource
- BridgeBio reports inducement grants under Nasdaq listing rule
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio price target lowered to $45 from $46 at Citi